Ontology highlight
ABSTRACT: Purpose
Outcome for patients with metastatic rhabdomyosarcoma (RMS) is poor. This study presents the results of the MTS 2008 study with a pooled analysis including patients from the concurrent BERNIE study.Patients and methods
In MTS 2008, patients with metastatic RMS received four cycles of ifosfamide, vincristine, and actinomycin D (IVA) plus doxorubicin, five cycles of IVA, and 12 cycles of maintenance chemotherapy (low-dose cyclophosphamide and vinorelbine). The BERNIE study randomly assigned patients to the addition or not of bevacizumab to the same chemotherapy. Local therapy (surgery/radiotherapy) was given to the primary tumor and all metastatic sites when feasible.Results
MTS 2008 included 270 patients (median age, 9.6 years; range, 0.07-20.8 years). With a
SUBMITTER: Schoot RA
PROVIDER: S-EPMC9649279 | biostudies-literature | 2022 Nov
REPOSITORIES: biostudies-literature